Cognition Therapeutics Inc.
2403 Sidney Street
Suite 261
Pittsburgh
Pennsylvania
15203
United States
Tel: 412-481-2210
Fax: 412-481-2216
Website: http://www.cogrx.com/
Email: info@cogrx.com
125 articles about Cognition Therapeutics Inc.
-
While it was a relatively quiet week for clinical trial announcements overall, BioSpace takes a look at some of the more intriguing ones.
-
Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812
6/23/2022
Cognition Therapeutics , Inc. (Nasdaq: CGTX) today announced that the first patient has been dosed in its double-blind, placebo-controlled, randomized Phase 2 SHIMMER clinical trial of CT1812 in patients with dementia with Lewy bodies (DLB).
-
Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference
6/8/2022
Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th.
-
Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation
6/2/2022
Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced plans to hold a virtual KOL symposium on June 9, 2022, from 10:00 - 11:30 a.m. ET to discuss dry age-related macular degeneration (dry AMD). Cognition plans to initiate a Phase 2 clinical study with CT1812, its lead sigma-2 (σ-2) receptor modulator, in patients with dry AMD in the second half of 2022.
-
Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference
5/13/2022
Cognition Therapeutics, Inc. will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.
-
Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
5/11/2022
Cognition Therapeutics, Inc. today reported financial results for the first quarter ended March 31, 2022 and provided recent business updates.
-
CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022
5/4/2022
Cognition Therapeutics, Inc. announced that it will report financial results for the first quarter ended March 31, 2022 in the form of a press release before the financial markets open on Wednesday, May 11, 2022.
-
Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022
5/4/2022
Cognition Therapeutics, Inc. announced that it will report financial results for the first quarter ended March 31, 2022 and provide a business update before the financial markets open on Tuesday, May 11, 2022.
-
Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration
4/25/2022
Cognition Therapeutics, Inc. (NASDAQ: CGTX), will be presenting a poster at the annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) summarizing preclinical results showing that sigma-2 (σ-2) receptor modulators protect RPE cells and normalize key homeostatic processes disrupted in dry age-related macular degeneration (dry AMD).
-
Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference
4/25/2022
Cognition Therapeutics, Inc. announced that members of its management team will participate in a virtual fireside chat at the B. Riley Securities’ Neuro & Ophthalmology Conference taking place from April 27-28, 2022.
-
Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference
4/6/2022
Cognition Therapeutics, Inc. announced that the company would be participating in Needham & Company’s 21st Annual Virtual Healthcare Conference being held April 11-14, 2022.
-
Susan Catalano, Ph.D., joined CODA Biotherapeutics as chief scientific officer after 14 years as CEO of Cognition Therapeutics, the company she founded in 2007 and took public in 2021.
-
Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update
3/30/2022
Cognition Therapeutics, Inc. today reported financial results for the year ended December 31, 2021 and provided recent business updates.
-
Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 ResultsConference Call and Live Audio Webcast Scheduled for Wednesday, March 30, 2022, 8:00 a.m. ET
3/22/2022
Cognition Therapeutics, Inc. today announced that the Company will release financial results for the fourth quarter and full year ended December 31, 2021 on Wednesday, March 30, 2022.
-
Cognition Therapeutics Announces Participation in March 2022 Investment Conferences
3/8/2022
Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, announced that the Company’s president and CEO, Lisa Ricciardi, will be participating at two upcoming conferences, details of which follow.
-
Cognition Therapeutics to Participate in Panel during the BIO CEO & Investor Conference on the Development of Neurodegenerative Therapeutics
2/8/2022
Cognition Therapeutics, Inc., a clinical-stage neuroscience company developing drugs that treat age-related degenerative diseases, announced that Anthony Caggiano, M.D., Ph.D., chief medical officer and head of R&D, will participate in a panel discussion during the annual BIO CEO & Investor Conference, entitled, “Exploring the Possibilities of Developing Neurodegenerative Therapeutics.” Joining Dr.
-
Cognition Therapeutics Provides Update on Corporate and Pipeline Progress and Reviews Goals for 2022
1/10/2022
Cognition Therapeutics, Inc. provided a summary of the Company’s 2021 accomplishments and outlined upcoming milestones anticipated in the year ahead.
-
Cognition Therapeutics Receives Grant from Michael J. Fox Foundation to Support Development of Sigma-2 Receptor Modulator for Parkinson’s Disease
1/4/2022
Cognition Therapeutics, Inc. today announced that the company has been awarded a Therapeutic Pipeline Program Grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF).
-
Cognition Therapeutics to Participate in Next-Generation Alzheimer’s Disease Panel at Virtual Biotech Showcase on January 11, 2022
12/21/2021
Cognition Therapeutics, Inc. today announced that Lisa Ricciardi, president and CEO of Cognition Therapeutics, will participate in a Biotech Showcase panel discussion.
-
Cognition Therapeutics to Host Virtual R&D Symposium December 7 on Dementia with Lewy Bodies and the Potential for Sigma-2 Modulation
11/30/2021
Cognition Therapeutics, Inc. will hold a virtual R&D symposium on December 7, 2021, from 10:00am – 12:00pm ET.